Merck shares ease; EMA CHMP backs Keytruda+Padcev for MIBC
Merck & Co. shares slipped after regulatory news. Keytruda contributed $8.37B of $16.61B in quarterly revenue, and the EMA CHMP backed KEYTRUDA+Padcev for perioperative MIBC.
Merck & Co. shares slipped after regulatory news. Keytruda contributed $8.37B of $16.61B in quarterly revenue, and the EMA CHMP backed KEYTRUDA+Padcev for perioperative MIBC.